CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...
Phase 2
Madrid, Spain and 83 other locations
to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...
Phase 3
Madrid, Spain and 52 other locations
Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer....
Phase 1
Madrid, Spain and 13 other locations
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Phase 1
Madrid, Spain and 24 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Madrid, Spain and 209 other locations
over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-sma ...
Phase 1
Madrid, Spain and 38 other locations
Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung...
Phase 1
Madrid, Spain and 38 other locations
locally advanced or metastatic disease.In addition, HER3-DXd will be evaluated in participants with locally advanced or metastatic NSCLC whose tumors...
Phase 1
Madrid, Spain and 35 other locations
the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung...
Phase 1, Phase 2
Madrid, Spain and 30 other locations
type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...
Phase 1, Phase 2
Madrid, Spain and 123 other locations
Clinical trials
Research sites
Resources
Legal